TherapeuticsMD, Inc.

TherapeuticsMD, Inc. (NASDAQ: TXMD) operates as a pharmaceutical royalty company focused on women's healthcare products. The company maintains its corporate website at www.therapeuticsmd.com.

The company transformed its business model in December 2022 when it completed a transaction with Mayne Pharma Group Limited, transitioning from a direct commercial pharmaceutical company to a royalty-based model. Under this arrangement, TherapeuticsMD licenses its product portfolio to third-party pharmaceutical organizations with established commercial capabilities while retaining the right to receive ongoing royalties on product sales.

TherapeuticsMD's primary revenue sources derive from three licensed products: IMVEXXY, an estradiol vaginal insert for treating moderate-to-severe dyspareunia associated with menopausal vulvar and vaginal atrophy; BIJUVA, a bioidentical hormone therapy combining estradiol and progesterone for treating moderate-to-severe vasomotor symptoms in menopausal women; and ANNOVERA, a one-year contraceptive vaginal system. The company also receives royalties on prescription prenatal vitamin products marketed under the vitaMedMD and BocaGreenMD brand names.

Mayne Pharma holds exclusive commercialization rights for these products in the United States and its territories under a license agreement providing for royalty payments of eight percent on the first eighty million dollars in annual net sales and seven point five percent on sales above that threshold, along with minimum annual royalties of three million dollars adjusted for inflation. The company has also entered into separate licensing agreements with Knight Therapeutics for Canada and Israel, and with Theramex for international markets outside the United States, Canada, and Israel.

As of December 31, 2025, TherapeuticsMD employed one full-time executive and engaged external consultants to support licensee relationships and manage financial, legal, and regulatory matters. The company's business model depends entirely on the commercial success of its licensees in marketing and distributing the licensed products. The company is classified as a smaller reporting company for SEC reporting purposes and is not a well-known seasoned issuer.